We don’t have to stay on this trajectory. But changing direction will require decisive moves from the U.S. government. As the global leader in pharmaceutical development, the U.S. has a moral obligation to lead the way on solving this global problem. We need to jump-start research and development on new antimicrobial drugs and shore up the patent system that enables us to bring so many new medicines to market.